Search clinical trials for: Elafibranor

Total 14 results

Ipsen

Completed

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet

Healthy Participants

France
Genfit

Terminated

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

United States
Ipsen

Active, not recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

Spain, United States, Italy, Canada, Germany, United Kingdom, Portugal
Ipsen

Completed

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Healthy Volunteers

United States
Genfit

Completed

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Healthy | Geriatrics

France
Genfit

Completed

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Kidney Diseases | Renal Insufficiency | Renal Impairment | Pharmacokinetics

France, Romania
Genfit
University of Miami; Syneos Health

Completed

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Pharmacokinetics | Hepatic Impairment | Liver Disease

United States
Genfit

Completed

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cholangitis (PBC)

United States, United Kingdom, France, Germany, Spain
Ipsen

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Primary Biliary Cholangitis (PBC)

United States, Spain, Korea, Republic of, Italy, France, Belgium, Australia, Czechia, Poland, Romania, New Zealand
Genfit

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
Genfit

Terminated

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Non-Alcoholic Fatty Liver

Netherlands
Ipsen

Active, not recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Primary Biliary Cirrhosis

United States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
Ipsen

Recruiting

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE)

Primary Biliary Cholangitis

United States, Germany, Spain, Korea, Republic of, Italy, Czechia, France, Poland, United Kingdom
Genfit

Completed

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Drug-drug Interaction

France

Search clinical trials for: Elafibranor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations